Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Consumer Cyclical Healthcare Technology Advertising Agencies Biotechnology Software - Application Cannabis
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Willow Biosciences Inc > Analyst Coverage
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by Bullknit101on Jul 12, 2022 12:37pm
217 Views
Post# 34818329

RE:RE:Analyst Coverage

RE:RE:Analyst Coverage Hard to trust analysts these days. They all seems to have a bullish bias as if they're promoting the stock price or they are just plain wrong. The narrative for cannabinoid biosybthesis is pretty good overall but the restraining forces are: US govt, FDA, consumer awareness, market demand, big pharma (existing drug market), pricing power not there. Etc...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities